Tango Therapeutics (TNGX) EBITDA Margin (2020 - 2025)
Tango Therapeutics (TNGX) posted quarterly EBITDA Margin of 26.15% for Q3 2025, up 30941.0% year-over-year from N/an in Q3 2024, and up 102.03% quarter-over-quarter from 1287.87% in Q2 2025.
Tango Therapeutics (TNGX) EBITDA Margin (2020 - 2025) Analysis & Trends
Tango Therapeutics' EBITDA Margin history runs 6 years deep, the most recent figure standing at 26.15% for Q3 2025.
- In Q3 2025, EBITDA Margin rose 30941.0% year-over-year to 26.15%; the TTM figure through Mar 2026 stood at 206.22% (up 14964.0% YoY), while the FY2025 annual figure was 178.39%, up 16769.0% from the prior year.
- EBITDA Margin for Q3 2025 stood at 26.15%, up from 1287.87% in the prior quarter.
- The five-year high for EBITDA Margin was 26.15% in Q3 2025, with the low at 1287.87% in Q2 2025.
- The 5-year median for EBITDA Margin is 432.41% (2022), against an average of 440.58%.
- Peak annual rise in EBITDA Margin reached 30941 bps in 2025, while the deepest fall reached 113918 bps in 2025.
- Tango Therapeutics' EBITDA Margin stood at 384.6% in 2021, then decreased by 24 bps to 476.79% in 2022, then plunged by 35 bps to 644.69% in 2023, then sank by 54 bps to 993.68% in 2024, then surged by 103 bps to 26.15% in 2025.
- Business Quant data shows TNGX's EBITDA Margin at 26.15% in Q3 2025, 1287.87% in Q2 2025, and 788.76% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 31.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 19.06% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,569,866.34% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.75% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 17.93% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.36% |
| 10 | Tango Therapeutics | 4.32 Bn | 3.30 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 26.15% |
| Jun 30, 2025 | -1,287.87% |
| Mar 31, 2025 | -788.76% |
| Dec 31, 2024 | -993.68% |
| Sep 30, 2024 | -283.26% |
| Jun 30, 2024 | -148.69% |
| Mar 31, 2024 | -652.99% |
| Dec 31, 2023 | -644.69% |
| Sep 30, 2023 | -238.78% |
| Jun 30, 2023 | -159.25% |
| Mar 31, 2023 | -525.25% |
| Dec 31, 2022 | -476.79% |
| Sep 30, 2022 | -432.41% |
| Jun 30, 2022 | -436.70% |
| Mar 31, 2022 | -440.76% |
| Dec 31, 2021 | -384.60% |
| Sep 30, 2021 | -288.33% |
| Jun 30, 2021 | -25.10% |
| Mar 31, 2021 | -189.18% |
| Dec 31, 2020 | -2.94% |